PatientSafe Solutions

pepidinternational.com

PatientSafe Solutions helps care teams communicate and work together reliably and efficiently through a mobile platform that unites clinical communication with workflows in one application, on one device. PatientTouch delivers secure messages, voice calls, critical alerts and nurse calls to a unified inbox prioritized for each care team member. The platform extends to include clinical workflows like rounding, specimen collection, sepsis and nursing documentation. Deeply integrated with the EMR, clinical, and directory systems, PatientTouch provides real-time patient, clinical and care team context for more efficient care collaboration and decision making. For more than a decade, PatientTouch has helped clinicians both in and outside the hospital streamline care delivery, increase quality and lower costs. For more information, please visit patientsafesolutions.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

news image

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

news image

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More

CELL AND GENE THERAPY

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

news image

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More
news image

RESEARCH

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More
news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More
news image

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More
news image

CELL AND GENE THERAPY

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More